Key facts
- It has raised $330.0M across 4 recorded rounds; the latest was PIPE ($230.0M) in Jan 2024.
- 5 institutional filers report fund marks on Dianthus Therapeutics across 32 filings.
- Dianthus Therapeutics has filed 5 Form Ds with the SEC since 2019, most recently Apr 2022 ($100.0M sold to 22 investors).
Free account
See the evidence behind this price
- ·Post-money valuations for all 4 rounds
- ·Watchlist + deal alerts for Dianthus Therapeutics
Create free account
No card required
Funding rounds
4 roundsJan 2024PIPE$230.0M▮
Apr 2022Early Stage VC (Series A)$100.0M▮
About Dianthus Therapeutics
- Industry
- Drug Discovery
PA Mark — not yet priced
Dianthus Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Pro members can request priority coverage with a 48-hour turnaround.
Recorded secondary trades
No prints on record
No secondary trades in Dianthus Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Pro members can request priority coverage with a 48-hour turnaround.
Institutional fund marks
5 filers · latest Jun 20265 SEC-registered funds reported 32 fair-value marks on Dianthus Therapeutics between Apr 2025 and Jun 2026. Filer-level marks and implied $/share are available to Pro members.